Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Titel:
Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Auteur:
Glassberg, Marilyn K. Nathan, Steven D. Lin, Chin-Yu Morgenthien, Elizabeth A. Stauffer, John L. Chou, Willis Noble, Paul W.